AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 272 min read$CODX

Brown Brian Lee sold (to issuer) $7K of CODX

Brown Brian Lee (Chief Financial Officer) sold (to issuer) 1,350 shares of Co-Diagnostics, Inc. (CODX) at $5.07 on 2026-05-23.

Original reporting
SEC EDGAR · Brown Brian Lee
Published May 27, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CODX
Neutral
medium confidence
Mentioned
$CODX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CODXNeutralLow
01

Why it matters

The disclosure updates insider ownership but does not include any new company-specific fundamentals (earnings, trials, contracts, or guidance).

02

Market read

Likely low trading relevance; any reaction should be muted absent additional operational news or larger insider/buyback activity.

03

What to watch

No 10b5-1 plan is stated, but the filing type and small dollar amount reduce interpretability; watch for repeated insider trades or larger buyback announcements.

Relevance 6/10Timing: Same-day disclosure (filed 2026-05-27) may cause minor sentiment read-through, but no fundamental catalyst is cited.

Background

The filing is an SEC Form 4 insider transaction for Co-Diagnostics, Inc., reporting a CFO sale to the issuer on 2026-05-23.

Company-level read

Ticker impact

$CODXNeutralMedium confidence
Context

Co-Diagnostics CFO Brown Brian Lee sold 1,350 shares to the issuer at $5.07/share, reducing holdings to 22,379 shares.

Expected impact

Limited near-term impact; any move is likely noise unless follow-on insider activity or buyback scale changes.

Evidence & confidence

Insider transactions can signal liquidity/portfolio management, but the article provides only a modest value (~$6.8k) and no operational or guidance catalyst.

Market effects

Sector

Minimal; single small insider transaction does not reset sector expectations for diagnostics.

Regional

None indicated; company-specific filing only.

Global

None indicated; no international deal/regulatory development mentioned.

Counterpoint

What could challenge this read

Because the transaction is coded as a sale to the issuer, it may reflect routine buyback participation rather than bearish conviction.

Key entities

  • issuer
    Co-Diagnostics, Inc.

    Subject of the Form 4 insider transaction; CFO sold shares to the issuer at $5.07/share.

  • insider
    Brown Brian Lee

    CFO who sold 1,350 shares; holdings after transaction: 22,379 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CODX insider trading history →

Related articles

OCT 27
$CODXMed

CoSara submits tuberculosis test for India regulatory review

Co-Diagnostics' India joint venture, CoSara, submitted its tuberculosis test for regulatory review in India, reporting 97.3% sensitivity and 96.0% specificity. The test, using Co-Diagnostics' technology, aims for approval by Q4 2026 to begin sales in India and South Asia. India has the highest tuberculosis burden globally, according to the WHO.

investing.com2 min
OCT 27
$CODXMedAI 8/10

Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India

Co-Diagnostics' joint venture CoSara Diagnostics completed a clinical study for its tuberculosis test, reporting 97.3% sensitivity and 96.0% specificity. The test was submitted to India's CDSCO for regulatory clearance, with a commercial launch anticipated before year-end 2026. The company has also deployed mobile and cloud infrastructure in India to support the launch.

prnewswire.com2 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min